Guardant Health (GH) is back in focus after the U.S. FDA approved its Guardant360 CDx liquid biopsy as a companion diagnostic for Boehringer Ingelheim’s HERNEXEOS in HER2 mutant advanced non small cell lung cancer.

The FDA decision appears to have arrived on top of already strong momentum, with a 30 day share price return of 33.67% and a 1 year total shareholder return of 167.03%, suggesting sentiment has shifted rapidly in Guardant Health’s favor.

If this kind of move has your attention, it could be a good moment to look at other specialized healthcare AI opportunities via our 40 healthcare AI stocks

With Guardant Health now trading at $131.62 and sitting roughly 7% below the average analyst price target and about 19% below some intrinsic value estimates, the key question is whether there is still a buying opportunity here or if the market is already pricing in future growth.

Most Popular Narrative: 3.1% Undervalued

Guardant Health's most followed narrative pegs fair value at $135.76, just above the last close of $131.62, which frames today’s debate around fine margins rather than a big mismatch.

Substantial regulatory, reimbursement, and clinical validation milestones (including Shield's breakthrough device status, NCCN guideline inclusion, and ongoing pilot studies) are paving the way for further guideline adoption, expanded payer coverage, and commercial inflections in Shield/MCED and Reveal volumes, significantly increasing future revenue and earnings visibility.

The fair value story rests on rapid revenue expansion, slimmer losses turning toward profit, and a future earnings multiple that is unusually high for healthcare. Curious what specific growth and margin assumptions sit under that price tag.

Result: Fair Value of $135.76 (UNDERVALUED)

However, the story can change quickly if high R&D spending keeps cash burn elevated or if reimbursement and payer adoption for Shield and other tests fall short.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Rich P/S Multiple Raises the Bar

While the SWS fair value model suggests Guardant Health is trading about 19% below estimated intrinsic value, the market price implies a very full P/S of 16.2x. That compares with a fair ratio of 7.6x, the US Healthcare industry at 1.3x, and peers around 1.4x, which places a lot of pressure on future growth and margins to deliver. Is that premium multiple a cushion or a tightrope for you?

Next Steps

With sentiment clearly split between opportunity and risk, this is the moment to move fast, compare the upside and downside yourself, and weigh the 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Guardant Health is on your radar, do not stop here. A broader watchlist can help you spot opportunities before they move and avoid concentration risk.

• Target potential mispricings by scanning quality stocks that still trade at a discount using the 44 high quality undervalued stocks.
• Strengthen your downside protection by focusing on companies highlighted in the 70 resilient stocks with low risk scores.
• Spot future standouts early by reviewing the screener containing 20 high quality undiscovered gems before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.